The goal of this clinical trial is to evaluate the efficacy of a topical peptide-based formulation containing Acetyl Hexapeptide-37 in promoting skin barrier recovery after controlled disruption in healthy adult participants.

The main questions it aims to answer are:

• Does the peptide cream speed up the recovery of the skin barrier after it has been slightly damaged with tape-stripping method?
• How does the peptide cream compare to a placebo (a cream with no active ingredient) in improving skin hydration and reducing redness?

Researchers will compare the peptide cream to a placebo to assess its effects on skin barrier recovery

Participants will:

• Undergo controlled disruption of the skin barrier on the volar forearm using the tape-stripping method.
• One forearm will receive the peptide-based cream containing Acetyl Hexapeptide-37, while the other (contralateral) forearm will receive a placebo formulation.
• Attend scheduled visits for non-invasive assessments of skin barrier function, including transepidermal water loss, skin hydration, and erythema

Inclusion Criteria:

• healthy volunteers who gave written informed consent

Exclusion Criteria:

• skin disease
• skin damage on measurement sites
• use of corticosteroids, antihistamines and immunomodulators a month prior the inclusion and during the trial
• use of emollients three days prior the inclusion in the trial
• non-adherence to the trial protocol
• exposure to artificial and excessive natural ultraviolet (UV) radiation
• pregnancy or breastfeeding
• immunosuppression
• allergic or irritant reactions to the constituents of the cream